Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?

Ron Ram; Anat Gafter-Gvili; Elimelech Okon; Idit Pazgal; Ofer Shpilberg; Pia Raanani

doi:10.1159/000121825

Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?

Ron Ram, Anat Gafter-Gvili, Elimelech Okon, Idit Pazgal, Ofer Shpilberg, Pia Raanani

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.

Original language	English
Pages (from-to)	104-107
Number of pages	4
Journal	Acta Haematologica
Volume	119
Issue number	2
DOIs	https://doi.org/10.1159/000121825
State	Published - 1 Apr 2008
Externally published	Yes

Keywords

Chronic myeloid leukemia
Gelatinous transformation
Imatinib

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000121825

Cite this

@article{51a011c5654843058897000fbf44e297,

title = "Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?",

abstract = "Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.",

keywords = "Chronic myeloid leukemia, Gelatinous transformation, Imatinib",

author = "Ron Ram and Anat Gafter-Gvili and Elimelech Okon and Idit Pazgal and Ofer Shpilberg and Pia Raanani",

year = "2008",

month = apr,

day = "1",

doi = "10.1159/000121825",

language = "English",

volume = "119",

pages = "104--107",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate

T2 - A disease or a drug effect?

AU - Ram, Ron

AU - Gafter-Gvili, Anat

AU - Okon, Elimelech

AU - Pazgal, Idit

AU - Shpilberg, Ofer

AU - Raanani, Pia

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.

AB - Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.

KW - Chronic myeloid leukemia

KW - Gelatinous transformation

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=42549123008&partnerID=8YFLogxK

U2 - 10.1159/000121825

DO - 10.1159/000121825

M3 - Article

AN - SCOPUS:42549123008

SN - 0001-5792

VL - 119

SP - 104

EP - 107

JO - Acta Haematologica

JF - Acta Haematologica

IS - 2

ER -

Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: A disease or a drug effect?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this